Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

Inclusion Criteria - Subjects with type 2 diabetes mellitus - On a stable regimen of metformin alone, metformin and a DPP4, metformin and a TZD, or metformin, a DPP4, and a TZD for a minimum of 3 months prior to randomization - Body mass indices > 25 and < 45 kg/m2 - Hemoglobin A1c levels ≥ 7.0% and ≤ 11.0% at screening - Fasting C-peptide levels ≥ 0.2 nmol/L at screening - Subject with a history of hypertension must be on a stable antihypertensive treatment (s) (type of medication, dose, and regimen) for at least 6 weeks prior to the first dose of investigational product - Other criteria may apply Exclusion Criteria - Subject has type 1 diabetes mellitus or history of type 1 diabetes mellitus - Subject has had 2 or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening - Poorly controlled hypertension defined as diastolic pressure ≥ 95 mmHg or systolic ≥ 155 mmHg (confirmed by a repeat assessment) at screening - Triglycerides ≥ 400 mg/dL (4.52 mmol/L) at screening - Use of any known cytochrome P450 (CYP) inducers within 30 days or 5 half-lives (whichever is longer), prior to receiving the first dose of investigational product. - Use of any known inhibitors of CYP3A4/P-glycoprotein within the 14 days or 5 half lives (whichever is longer) prior to receiving the first dose of investigational product - Other criteria may apply